Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunotoxins.

O W Press1

  • 1Department of Medicine, University of Washington, Seattle.

Biotherapy (Dordrecht, Netherlands)
|January 1, 1991
PubMed
Summary
This summary is machine-generated.

Immunotoxins (ITs) are engineered cancer therapies combining antibodies and toxins. Their effectiveness relies on efficient cell entry and protein synthesis inhibition, with clinical trials showing promise.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma.

Bone marrow transplantation·2016
Same author

A randomized study of melphalan 200 mg/m(2) vs 280 mg/m(2) as a preparative regimen for patients with multiple myeloma undergoing auto-SCT.

Bone marrow transplantation·2015
Same author

Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

Well-defined single polymer nanoparticles for the antibody-targeted delivery of chemotherapeutic agents.

Polymer chemistry·2015
Same author

Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes.

Leukemia·2015
Same author

Improving the chance of cure of follicular lymphoma by combining immunotherapy and radioimmunotherapy based on anti-CD20 antibodies?

Annals of oncology : official journal of the European Society for Medical Oncology·2013
Same journal

Cytokine effect on ex vivo expansion of haemopoietic stem cells from different human sources.

Biotherapy (Dordrecht, Netherlands)·1999
Same journal

Elevated serum level of thioredoxin in patients with hepatocellular carcinoma.

Biotherapy (Dordrecht, Netherlands)·1999
Same journal

Contribution of cytokines on the suppression of lung metastasis.

Biotherapy (Dordrecht, Netherlands)·1999
Same journal

Antitumor effect of a peptide-glucan preparation extracted from Agaricus blazei in a double-grafted tumor system in mice.

Biotherapy (Dordrecht, Netherlands)·1999
Same journal

Levamisole and interleukin-2 for advanced malignancy.

Biotherapy (Dordrecht, Netherlands)·1999
Same journal

The use of BRM-activated killer cells in adoptive immunotherapy: a pilot study with nine advanced cancer patients.

Biotherapy (Dordrecht, Netherlands)·1999
See all related articles

Area of Science:

  • Oncology
  • Molecular Biology
  • Biotechnology

Background:

  • Immunotoxins (ITs) are investigational therapeutics.
  • They combine monoclonal antibodies (MoAbs) for tumor targeting with cytotoxic payloads (e.g., ricin, pseudomonas exotoxin).
  • ITs aim to selectively eliminate cancer cells by inhibiting protein synthesis.

Purpose of the Study:

  • To review the mechanisms of immunotoxin action.
  • To highlight the importance of intracellular trafficking and translocation for IT efficacy.
  • To discuss the current status of ITs in cancer treatment.

Main Methods:

  • Review of existing literature on immunotoxin design and function.
  • Analysis of in vitro and in vivo experimental data.
  • Summary of clinical trial outcomes.

Related Experiment Videos

Main Results:

  • ITs demonstrate specific tumor targeting via MoAb binding.
  • Cytotoxic payload delivery to the cytosol is critical for cell killing.
  • Endocytosis rates, intracellular routing, and translocation efficiency significantly impact IT efficacy.
  • Promising preclinical and early clinical results have been reported.

Conclusions:

  • Immunotoxins represent a promising strategy in targeted cancer therapy.
  • Optimizing intracellular delivery pathways is key to enhancing IT effectiveness.
  • Ongoing phase I clinical trials are evaluating the safety and efficacy of ITs in cancer patients.